Novel arm‐width‐expandable transcatheter edge‐to‐edge repair system: Preclinical experiment and first‐in‐human study
Catheterization and Cardiovascular Interventions · 2023
DOI: 10.1002/ccd.30758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2023. Verfasst von Yuliang Long und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Research Unit of Cardiovascular Techniques and Devices, Chinese Academy of Medical Sciences, Fudan Univ…. Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Mitral Valve Insufficiency. Die Arbeit nennt 15 Literaturangaben. Gefördert von: State Key Clinical Specialty Construction Project, National key R&D Program of China.
Abstract (Originalsprache)
Background
The ValveClasp system is a novel transcatheter edge‐to‐edge repair (TEER) device with an arm‐width‐expandable clip that allows treatment of patients with only one clip more frequently.
Objectives
This study aimed to evaluate the feasibility and safety of a novel TEER device in porcine models and patients.
Methods
Fourteen young adult pigs were enrolled. A clip with an expanded arm was implanted under epicardial echocardiography and fluoroscopy guidance. Five patients with at least moderate‐to‐severe mitral regurgitation underwent TEER using the ValveClasp system to test the safety and effectiveness of the device.
Results
The device success rate was 100% (14/14) in the animal experiments, and all clips were deployed at the A2P2 segments, forming a double‐orifice mitral valve. Gross observations on day 180 showed a wide and continuous tissue bridge between the leaflets. The acute procedural success rate was 100% (5/5). Only one clip was required in all patients, and all achieved effective postoperative endpoints (grade ≤2+). During 30‐day follow‐up, no adverse events occurred. All patients' vena Contracta width (from 8.04 0.71 mm to 3.84 ± 1.18 mm, p = 0.012), mitral regurgitation area (from 12.75 ± 3.13 cm 2 to 3.50 ± 1.66 cm 2 , p = 0.008), and left ventricular end diastolic diameter (from 52.00 ± 2.92 mm to 46.00 ± 3.08 mm, p = 0.040) were considerably decreased, without obvious mitral stenosis.
Conclusions
The novel arm‐width‐expandable ValveClasp device is safe for TEER for treating severe mitral regurgitation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Research Unit of Cardiovascular Techniques and Devices, Chinese Academy of Medical Sciences, Fudan University, Shanghai, China.
- National Clinical Research Center for Interventional Medicine, Shanghai, China.
- Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Shiqiang Hou, Daxin Zhou
Förderung
- State Key Clinical Specialty Construction Project
- National key R&D Program of China
Zitieren
APA
Long, Y., Li, W., Chen, S., Li, M., Hou, S., Pan, C., Zhou, D., Pan, W., & Ge, J. (2023). Novel arm‐width‐expandable transcatheter edge‐to‐edge repair system: Preclinical experiment and first‐in‐human study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30758
Vancouver
Long Y, Li W, Chen S, Li M, Hou S, Pan C, et al. Novel arm‐width‐expandable transcatheter edge‐to‐edge repair system: Preclinical experiment and first‐in‐human study. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30758
BibTeX
@article{Long2023,
author = {Long, Yuliang and Li, Wei and Chen, Shasha and Li, Mingfei and Hou, Shiqiang and Pan, Cuizhen and Zhou, Daxin and Pan, Wenzhi and Ge, Junbo},
title = {Novel arm‐width‐expandable transcatheter edge‐to‐edge repair system: Preclinical experiment and first‐in‐human study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2023},
doi = {10.1002/ccd.30758}
}
EUVIMED